Clinical Insights on R/R Follicular Lymphoma: ASH 2024 Highlights - Episode 8
Choosing Bispecifics in 3L Treatment Setting R/R FL
Panelists discuss the use of bispecifics in the third-line setting for relapsed/refractory follicular lymphoma (R/R FL), exploring how often they are utilized and how bispecifics fit into the treatment paradigm compared with other options like chimeric antigen receptor (CAR) T, EZH2 inhibitors, and Bruton tyrosine kinase (BTK) inhibitors.
Video content above is prompted by the following:
- Moving into in the third-line setting, we have many options now including CAR T, bispecifics, EZH2 inhibitors, BTK inhibitors; let’s first focus on the bispecifics. Dr Khan, how often are you utilizing the bispecifics in the R/R FL setting? How do the bispecifics fit into your treatment paradigm compared with these other agents?
- What factors influence your decision when selecting between mosunetuzumab and epcoritamab?
- When selecting between mosunetuzumab and epcoritamab what are key factors to consider?